Skip to main content

Advertisement

Table 3 Primary and secondary end-points after coronary angiographya

From: N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial

  NAC group(n = 45) Placebo group(n = 45b) P value
Primary end-point    
   Incidence of CIN, n(%) 5(11.1%) 6(14.3%) 0.656
Secondary end-points    
   Change in serum creatinine, mg/dL -0.016 ± 0.363 -0.018 ± 0.467 0.975
   Change in serum urea nitrogen, mg/dL -1.73 ± 24.03 -3.71 ± 24.26 0.703
   Change in creatinine clearance, mL/min 2.86 ± 8.84 3.78 ± 10.87 0.676
  1. a All plus-minus values are mean ± SD. CIN, contrast-induced nephropathy.
  2. bWhile 45 patients were enrolled in each group, serum creatinine and urea nitrogen measurements were not available for 3 placebo patients who were discharged immediately after coronary angiography and did not return for subsequent blood sampling (comparison, 45 NAC patients vs. 42 placebo patients).